Microbia, Forest ink $330M deal
Microbia is pocketing a $70 million up front payment from Forest Laboratories in exchange for a 50/50 U.S. development pact for linaclotide, an experimental therapy for irritable bowel syndrome and other gastrointestinal problems. Forest gains exclusive rights to the drug in Canada and Mexico and will help pay development costs. If all goes according to plan, Microbia will garner up to $330 million in the deal. The therapy is currently in Phase IIb. Microbia was a 2006 Fierce 15 company.
- see the release on the deal
Related Articles:
Microbia lands whopping $75M fifth round. Report
Forest Labs dumps failed stroke drug program. Report
Forest buys Cerexa in $480M deal. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
